Completed PHASE3 INTERVENTIONAL 2-arm NCT01147939

Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML) (CLAVELA)

A Randomised Phase III Study of Elacytarabine vs. Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia

Sponsor: Clavis Pharma

Conditions Acute Myeloid Leukemia (AML)

Interventions Elacytarabine Investigator's Choice

Updated 8 times since 2017 Last updated: Sep 20, 2013 Started: Jun 30, 2010 Primary completion: Feb 28, 2013 Completion: Jun 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Acute Myeloid Leukemia (AML), this trial is completed. The trial is conducted by Clavis Pharma and has accumulated 8 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Apr 2022 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Apr 2022 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jun 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Clavis Pharma

Data source: Clavis Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Badalona, Spain , Bergen, Norway , Berlin, Germany , Bonn, Germany , Bristol, United Kingdom , Bruges, Belgium , Brussels, Belgium , Bucharest, Romania , Chicago, United States and 57 more locations